Qiming Venture Partners, a China-based venture capital firm specialized in building new companies in China, led a $35m Series A round in TandemAI, an advanced technology company dedicated to reinventing drug discovery infrastructure, with participation from OrbiMed, Eight Roads Ventures, and F-Prime Capital. “Innovations continue to emerge in the space of AI drug discovery, and TandemAI is working to address the significant barriers to both accessing the most advanced computational tools and integrating them with biological and chemistry expertise. The rapid growth of TandemAI’s client base since its founding 15 months ago reflects that interest and the potential value the company’s approach brings to accelerating drug discovery,” Kan Chen, Qiming Venture Partners Partner.